Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Short term Debt (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Short term Debt for 4 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Short term Debt changed N/A to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10.0 million for FY2025, N/A changed from the prior year.
  • Short term Debt hit $10.0 million in Q4 2025 for Axsome Therapeutics, down from $70.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $70.0 million in Q2 2025 to a low of $5.9 million in Q4 2022.
  • Historically, Short term Debt has averaged $16.0 million across 4 years, with a median of $6.8 million in 2022.
  • Biggest five-year swings in Short term Debt: dropped 4.69% in 2023 and later soared 894.32% in 2025.
  • Year by year, Short term Debt stood at $5.9 million in 2022, then grew by 8.59% to $6.4 million in 2023, then rose by 26.91% to $8.1 million in 2024, then increased by 23.13% to $10.0 million in 2025.
  • Business Quant data shows Short term Debt for AXSM at $10.0 million in Q4 2025, $70.0 million in Q3 2025, and $70.0 million in Q2 2025.